View transcript
Today’s drug candidates are more complex than ever. But with development decisions on the line, measuring versatile solution that a versatile solution that everyone, including regulators, can trust. Enter Certara’s Phoenix platform, the industry’s first choice for turning PKPD data into results. Let’s explore.
Phoenix Winnonlin sets the standard for noncompartmental analysis, reusable workflows for data import, preparation, analysis, and submission ready reporting streamlined studies, saving time and reducing errors. Different patients mean different pharmacokinetics and pharmacodynamics.
Phoenix NLME offers the population PK analyst a range of tools for nonlinear mixed effects modeling. Whether through menu driven interfaces or R packages, users of all skill sets leverage the same powerful modeling engine. Models are a must, but prediction is power. The Phoenix IVIVC toolkit extrapolates in vitro properties to in vivo responses so you can rapidly assess bioequivalence, ensure manufacturing quality, and run fewer animal studies.
Looking for performance at scale? Phoenix Hosted is your fully managed environment running level three validated software trusted by the FDA. With automatic upgrades and fast remote processing, our hosted solution frees scientists and IT professionals to focus on the work that matters. More than ten thousand users at organizations worldwide trust Phoenix for high quality analysis, including the FDA, ten ex US regulatory agencies, and more than seventy of the top one hundred drug companies globally.
Ready to join them? Learn more at certara dot com slash phoenix.
You May Also Like
